Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis - Top-Institutions - MDSpire

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis

  • By

  • Sophie Buhelt

  • Malene Bredahl Hansen

  • Helle Bach Søndergaard

  • Sahla El Mahdaoui

  • Marie Mathilde Hansen

  • Mie Reith Mahler

  • Jeppe Romme Christensen

  • Finn Sellebjerg

  • June 5, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Copenhagen University Hospital – Rigshospitalet
    Copenhagen University Hospital – Rigshospitalet

    Copenhagen, Denmark

    Key Differentiators

    • Neurology

  • #2

    Danish Multiple Sclerosis Center
    Danish Multiple Sclerosis Center

    Copenhagen, Denmark

    Key Differentiators

    • Neurology

  • #3

    Ethics Committee of the University of Freiburg
    Ethics Committee of the University of Freiburg

    Freiburg, Germany

    Key Differentiators

    • Ethics

  • #4

    University Medical Center Freiburg
    University Medical Center Freiburg

    Freiburg, Germany

    Key Differentiators

    • Neurology

  • #5

    University Hospital Policlinico of Bari
    University Hospital Policlinico of Bari

    Bari, Italy

    Key Differentiators

    • Neurology

Original Source(s)

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis

  • by Sophie Buhelt, Malene Bredahl Hansen, Helle Bach Søndergaard, Sahla El Mahdaoui, Marie Mathilde Hansen, Mie Reith Mahler, Jeppe Romme Christensen, Finn Sellebjerg

  • June 5, 2026

Related Content

Cognitive Function and Fatigue in Stable Multiple Sclerosis: EDSS and MRI Assessments Surpass Serum Biomarkers

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Stem cell-derived extracellular vesicles as immunomodulatory agents: targeting pathological crosstalk in systemic lupus erythematosus and multiple sclerosis